AUTOLUS THERAPEUTICS LTD (NASDAQ: AUTL)

AUTOLUS THERAPEUTICS LTD

NASDAQ: AUTL (Autolus Therapeutics plc)

Last update: 29 May, 10:10AM

1.76

0.11 (6.36%)

Add to watchlist

Previous Close	1.65
Open	1.69
Volume	810,755
Avg. Volume (3M)	1,968,232
Market Cap	467,077,440

Price / Sales	79.16
Price / Book	1.92

52 Weeks Range	1.11 (-37%) — 5.00 (184%)
Earnings Date	8 Aug 2025 - 22 Aug 2025

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Mixed	Bearish
	Biotechnology (Global)	Mixed	Bearish
Stock	Autolus Therapeutics plc	Mixed	Mixed

AIStockmoo Score

0.0

Analyst Consensus	2.5
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	-2.5
Technical Oscillators	2.0
Average	0.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
AUTL	467 M	-	-	1.92
ASND	10 B	-	-	-
LEGN	8 B	-	-	7.99
MAZE	720 M	-	235.00	2.65
RAPP	607 M	-	-	1.98
AARD	292 M	-	-	1.67

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Sector	Healthcare
Industry	Biotechnology
% Held by Insiders	18.09%
% Held by Institutions	90.89%

Ownership

Name	Date	Shares Held
Syncona Portfolio Ltd	31 Dec 2024	16,640,720

52 Weeks Range	1.11 (-37%) — 5.00 (184%)
Median	10.00 (469.80%)
Total	1 Buy

Firm	Date	Target Price	Call	Price @ Call
Needham	21 Jul 2025	10.00 (469.80%)	Buy	2.43
Needham	12 Jun 2025	10.00 (469.80%)	Buy	2.15

No data within this time range.

Date	Type	Details
31 Jul 2025	Announcement	European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics
24 Jul 2025	Announcement	Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
21 Jul 2025	Announcement	Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
15 Jul 2025	Announcement	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jun 2025	Announcement	Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
29 May 2025	Announcement	Autolus Therapeutics to Participate in Upcoming Investor Conferences
23 May 2025	Announcement	Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
14 May 2025	Announcement	Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
08 May 2025	Announcement	Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Operating Margin (TTM)	-726.31%
Diluted EPS (TTM)	-0.880
Quarterly Revenue Growth (YOY)	-11.00%

Total Debt/Equity (MRQ)	83.84%
Current Ratio (MRQ)	9.24
Operating Cash Flow (TTM)	-241.32 M
Levered Free Cash Flow (TTM)	-214.39 M

Return on Assets (TTM)	-20.27%
Return on Equity (TTM)	-49.97%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)